Clinical research firm Bio-Images Research has appointed a director of regulatory affairs.
Dr Sarah Connolly, who has been with the Glasgow-based company for the past four years, will take responsibility for GMP, regulatory and ethical approvals.
The appointment is designed to maintain the highest level of ethical and regulatory standards as the company's pipeline of clinical studies steadily increases.
Bio-Images has completed three clinical studies this year and claims to be in the forefront of a small field of providers of gamma scintigraphy imaging services, which allow multi-national pharma companies to outsource some of their clinical research.
Dr Connolly joined the company after completing her PhD in Pharmaceutical Sciences at the University of Strathclyde in 2007.
Bio-Images Research appoints director of regulatory affairs
To maintain highest level of ethical standards as firm expands
You may also like
Regulatory
Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria
Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
Regulatory
Pfizer strikes landmark deal with US government to lower drug prices
The agreement ensures Americans pay less for medicines while giving Pfizer tariff certainty and a clear pricing framework, enabling $70bn in US investment and a renewed focus on next-generation therapies in cancer, obesity, vaccines and immunology
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)
With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases